Skip to main content
. 2012 Oct;92(4):775–785. doi: 10.1189/jlb.1011522

Table 2. List of All Genes Significantly Up-Regulated (P<10−5) by K and D ODNs.

Gene symbol K ODN
D ODN
1 h 3 h 9 h 27 h 1 h 3 h 9 h 27 h
ACSL1 0.9 2.3 6.8 2.7 1.3 0.9 1.6 3.5
ADAR 1.1 1.2 2.4 2.3 1.3 1.5 2.5 3.8
AKAP2 1.3 1.3 2.1 1.3 1.7 1.8 2.3 2.5
AKT1S1 1.0 1.3 4.0 2.6 1.8 2.6 2.1 2.4
ALG2 1.3 1.9 3.2 2.1 1.7 1.9 2.3 3.4
ARHGEF3 1.7 2.8 4.3 3.3 1.3 2.3 3.1 5.4
AZI2 1.1 1.5 2.7 1.5 1.0 1.2 1.6 3.3
B2M 1.0 1.4 3.3 2.9 1.2 1.1 1.6 3.0
B3GNT2 1.1 3.6 6.0 2.6 1.2 1.7 2.7 5.0
CBWD5 1.1 1.3 2.7 1.8 1.3 1.3 1.9 3.3
CHMP5 1.3 1.7 5.6 4.4 1.3 1.6 3.2 6.9
CYLD 1.1 1.9 3.2 2.2 1.0 1.3 1.6 3.2
DCK 1.3 1.1 2.4 1.4 1.2 1.3 1.5 3.3
DDX58 1.1 3.1 20.7 6.8 1.0 2.2 3.9 11.2
DDX60 0.9 0.9 7.0 7.6 0.8 0.8 2.6 11.8
DHX58 0.8 2.5 5.9 2.8 0.9 0.9 2.3 6.0
DTX3L 1.2 1.8 3.2 2.6 1.2 1.8 2.1 2.9
DYNLT1 0.9 1.4 3.9 1.8 1.0 0.8 1.5 3.3
EIF2AK2 1.4 2.0 4.3 4.2 0.9 1.0 2.0 3.2
EPSTI1 1.0 2.2 35.3 34.3 0.8 1.3 8.3 37.8
FYTTD1 1.1 1.3 2.8 1.7 1.1 1.2 1.5 2.5
GCH1 1.1 1.6 4.6 1.9 1.2 1.6 1.8 3.2
GMPR 1.2 1.8 6.8 5.1 1.2 1.5 3.4 7.2
GNB4 0.9 1.2 2.4 1.5 1.4 1.1 1.9 3.6
H3F3A/B 1.1 3.0 8.1 4.9 1.1 1.4 2.6 6.9
HERC5 1.1 2.6 16.9 10.1 0.9 1.1 3.4 14.3
HLA-A 0.9 1.4 3.2 3.5 1.3 1.7 1.7 4.4
HLA-C 0.8 1.4 3.5 3.5 1.4 1.8 2.1 6.1
HLA-G 0.9 1.5 3.7 3.4 1.1 1.2 1.8 3.7
IFI6 0.9 1.2 10.2 10.2 0.7 0.8 1.8 10.1
IFI44 0.9 2.5 15.5 37.7 0.9 0.9 8.2 36.1
IFI44L 0.9 2.4 7.4 11.5 0.8 1.2 4.2 8.2
IFIH1 1.1 5.2 30.8 12.2 0.9 1.6 4.4 17.4
IFIT1 1.2 13.7 23.4 9.5 0.1 5.7 9.8 19.9
IFIT2 1.2 39.6 42.0 23.6 0.9 6.6 5.2 16.2
IFIT3 0.8 3.5 5.1 6.3 0.9 2.7 5.3 7.6
IFIT5 0.8 5.6 8.2 3.9 0.9 1.4 2.5 7.2
IFITM2 1.0 1.9 8.9 11.4 1.1 1.7 5.0 21.3
IRF7 1.2 2.2 4.6 5.4 1.4 1.6 3.3 4.5
ISG15 1.2 6.0 24.8 35.8 1.1 2.2 9.9 30.2
ISG20 0.9 2.3 15.6 12.3 0.9 1.4 4.1 14.9
KIAA0040 0.9 1.5 3.3 1.6 1.0 1.1 2.1 3.5
LAP3 1.0 1.5 4.8 3.0 0.9 1.2 2.4 5.6
MASTL 1.0 2.5 4.1 1.9 1.3 1.0 2.5 3.3
MFN1 1.0 1.3 2.4 1.7 1.0 0.9 1.3 2.3
MT1F 1.4 1.5 2.4 2.1 1.6 1.5 1.3 2.0
MX1 1.1 4.9 27.1 31.6 0.9 1.4 11.7 29.3
NCOA7 1.4 2.3 5.0 2.4 1.1 1.4 2.1 4.4
NFKB1 0.9 2.4 4.6 2.3 1.0 1.2 1.6 3.1
NFYB 1.4 1.3 2.8 1.4 1.1 1.5 1.6 3.3
NLRC5 1.0 1.0 2.6 1.9 0.8 0.9 2.1 2.7
NMI 1.4 1.3 3.5 2.6 1.2 1.5 2.2 4.4
NT5C3 1.1 3.2 34.1 20.0 0.6 1.0 2.7 15.6
NUB1 0.9 1.3 2.1 1.9 1.0 1.1 1.6 2.2
OAS2 1.0 6.4 30.9 46.2 1.3 2.4 18.9 56.8
OAS3 0.9 1.3 7.7 5.7 0.8 0.8 2.6 8.2
PARP9 0.8 3.0 13.5 6.1 0.8 1.4 4.3 10.9
PARP12 0.9 2.6 7.2 4.7 0.7 0.9 1.4 3.3
PARP14 1.2 3.6 13.9 16.3 1.3 2.0 8.7 21.0
PI4K2B 1.0 2.1 4.5 2.3 0.8 1.1 1.4 2.9
PNPT1 1.0 1.8 7.8 3.8 1.0 1.2 2.3 6.3
PSMA2 1.2 1.1 2.6 2.0 1.3 1.5 1.7 3.3
PSMA4 1.0 0.9 3.2 1.7 1.1 1.3 1.6 2.9
RABGAP1L 1.1 1.4 4.7 3.3 1.1 1.2 2.4 6.5
RBBP6 0.8 1.4 2.4 1.2 0.9 1.0 1.2 2.0
RGL1 1.4 4.0 8.9 5.8 1.2 2.1 2.8 5.8
RHOH 1.2 1.6 2.1 1.0 1.2 1.8 2.0 2.7
RNF213 1.0 1.6 7.8 5.2 0.9 1.1 2.8 7.4
SAMD9 0.9 5.7 16.5 6.6 1.0 1.2 2.6 8.9
SAMD9L 1.0 11.1 33.5 17.2 0.5 1.2 3.8 15.9
SAT1 1.1 1.7 6.2 3.5 1.0 1.3 1.8 5.2
SLAMF7 1.1 2.8 5.0 4.4 1.2 1.8 2.3 3.3
SP100 1.0 2.0 5.6 3.0 1.1 1.4 2.4 4.8
SP110 1.5 2.9 7.0 7.4 1.4 2.4 5.9 10.0
SPATS2L 1.1 0.9 3.2 2.3 0.9 0.9 2.0 5.7
STAP1 1.2 2.1 5.6 4.4 1.3 1.4 3.1 5.5
STAT1 1.0 6.4 24.1 14.9 0.9 1.6 7.2 22.5
STX11 1.1 1.6 2.7 1.8 1.3 1.4 1.7 2.0
TAP1 0.8 2.0 4.8 3.5 1.2 0.8 2.4 4.3
TDRD7 1.2 2.2 8.4 4.5 1.0 1.3 2.7 9.0
TMCC3 1.2 1.3 4.2 4.8 0.7 0.7 1.8 4.8
TNFSF10 1.4 5.6 7.3 9.7 1.0 3.8 5.1 11.8
TNK2 1.0 1.4 2.5 2.2 1.2 1.4 1.9 2.6
TRAFD1 1.1 1.6 3.2 2.1 1.3 1.4 2.2 3.0
TRIM21 1.3 3.5 4.6 3.8 1.3 2.2 3.5 5.2
TRIM22 0.9 1.2 6.6 5.4 0.9 1.3 2.9 11.4
UBE2L6 1.0 2.6 17.6 13.5 0.9 1.3 4.9 28.4
UPK3BL 1.0 1.2 2.5 2.2 1.2 1.1 1.6 2.8
USP25 1.1 1.1 2.9 2.1 1.2 1.2 1.8 2.9
XRN1 1.2 1.4 4.0 2.0 1.1 1.0 1.9 4.0
ZNF385B 0.8 1.2 2.3 1.3 1.7 2.5 2.9 1.6
ZNFX1 1.1 2.3 3.5 2.5 1.1 1.5 2.3 2.7

CAL-1 cells were stimulated as described in Fig. 2. All genes up-regulated significantly by K and D ODNs (n=92) at any time-point are shown. Shown in bold are those genes that contribute to antiviral immunity (n=23; GO analysis). The level of gene induction is expressed as the fold increase compared with untreated cells.